GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®
Category: #health  | By Mateen Dalal  | Date: 2019-11-11 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®

GW Pharmaceuticals plc has reportedly announced that two of its medicines, Sativex (nabiximols) and EPIDYOLEX (cannabidiol) oral solution, have been advised by National Institute for Health and Care Excellence (NICE) of the U.K. to get routine compensation from NHS England.

Apparently, for the first-time any plant-derived cannabis-based drug has been advised by NICE for use on NHS. Cannabidiol oral solution is suggested as an adjunctive treatment for seizures related to Dravet syndrome or Lennox Gastaut syndrome (LGS), in conjunction with clobazam, for patients aged two years and older. In addition, Nabiximols, assessed as part of NICE’s analysis of cannabis-based medicinal products (CBMPs), has been considered economical for treatment of spasticity caused by multiple sclerosis.

Chris Tovey, Chief Operating Officer, GW, reportedly stated that this is a significant event for patients and families in the U.K. who have waited since a very long time for rigorously tested, proved and regulatory approved cannabis-based medication to be reimbursed by NHS. The recommendation by NICE has proved that cannabis-based drugs can effectively go through extensive randomized placebo-controlled tests and a rigorous evaluation process of NICE to reach patients.

Reportedly, cannabidiol oral solution has secured approval based on outcomes from four randomized, controlled Phase III studies. These trials include data from over 714 patients with either Dravet or LGS syndrome. Both the diseases are two rare forms of epilepsy with high mortality and morbidity rates, which considerably burdens caregivers and families. Several patients with Dravet or LGS syndrome go through multiple seizures per day, which increase the ongoing risk of injury and falls. Regardless of current anti-epileptic drug therapy, both of these rare forms of epilepsy have remained as extremely treatment resistant.

According to reliable sources, after the approval, GW has been functioning with the related bodies in Germany, the U.K., Spain, Italy, and France. The company intends to obtain reimbursement before anticipated launch of medication in these nations.
 

Source credits:

http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-receives-positive-nice-recommendation

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...